Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Teva Pharmaceutical Industries announced a shared commitment with the Trump Administration to negotiate an agreement aimed at lowering the cost of select medicines for U.S. Medicaid patients. The proposed deal, referred to as the GENEROUS framework, would align U.S. Medicaid pricing with leading developed markets and include a Most-Favored-Nation commitment for future innovative product launches.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.